Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis

Omar Hyder, J. Wallis Marsh, Riad Salem, Elena N. Petre, Sanjeeva Kalva, Eleni Liapi, David Cosgrove, Donielle Neal, Ihab Kamel, Andrew X. Zhu, Constantinos T. Sofocleous, Jean Francois H Geschwind, Timothy M. Pawlik

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: Many patients with intrahepatic cholangiocarcinoma (ICC) present with advanced and inoperable disease. Data on the safety and efficacy of intra-arterial therapy (IAT) for ICC are limited. Methods: Between 1992 and 2012, a total of 198 patients with advanced ICC treated with IAT were retrospectively identified from the databases of five major hepatobiliary institutions. Data on clinicopathological factors, morbidity, response rates, and overall survival were collected and analyzed. Results: Median patient age was 61 years. Median tumor size was 8.1 cm, and 47.5 % patients had a solitary lesion. IAT consisted of conventional transarterial chemoembolization (cTACE) (64.7 %), drug-eluting beads (DEB) (5.6 %), bland embolization (TAE) (6.6 %), or yttrium-90 radioembolization (23.2 %). Median number of IAT sessions was 2 (range 1-8). The median time between IAT sessions was 48 days. The periprocedural morbidity was 29.8 %; most complications were minor (n = 43); however, 16 patients had a grade 3-4 complication. Assessment of tumor response revealed complete or partial response in 25.5 % patients, while 61.5 % had stable disease; 13.0 % had progressive disease. Median overall survival was 13.2 months and did not differ on the basis of the type of IAT (cTACE, 13.4 months vs. DEB 10.5 months vs. TAE, 14.3 months vs. yttrium-90, 11.3 months; P = 0.46). IAT response on modified response evaluation criteria in solid tumors (mRECIST; hazard ratio for complete-partial response 0.49, 95 % confidence interval 0.30-0.81; P < 0.001) was independently associated with better survival. Conclusions: IAT for ICC was safe and led to stable disease or partial to complete response in up to three-quarters of patients. Among patients with an IAT response, overall survival was prolonged. The role of IAT therapy for ICC warrants further prospective evaluation in clinical trials.

Original languageEnglish (US)
Pages (from-to)3779-3786
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number12
DOIs
StatePublished - Nov 2013

Fingerprint

Cholangiocarcinoma
Therapeutics
Yttrium
Survival
Morbidity
Pharmaceutical Preparations
Neoplasms
Survival Rate
Clinical Trials
Databases
Confidence Intervals
Safety

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Hyder, O., Marsh, J. W., Salem, R., Petre, E. N., Kalva, S., Liapi, E., ... Pawlik, T. M. (2013). Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis. Annals of Surgical Oncology, 20(12), 3779-3786. https://doi.org/10.1245/s10434-013-3127-y

Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma : A multi-institutional analysis. / Hyder, Omar; Marsh, J. Wallis; Salem, Riad; Petre, Elena N.; Kalva, Sanjeeva; Liapi, Eleni; Cosgrove, David; Neal, Donielle; Kamel, Ihab; Zhu, Andrew X.; Sofocleous, Constantinos T.; Geschwind, Jean Francois H; Pawlik, Timothy M.

In: Annals of Surgical Oncology, Vol. 20, No. 12, 11.2013, p. 3779-3786.

Research output: Contribution to journalArticle

Hyder, O, Marsh, JW, Salem, R, Petre, EN, Kalva, S, Liapi, E, Cosgrove, D, Neal, D, Kamel, I, Zhu, AX, Sofocleous, CT, Geschwind, JFH & Pawlik, TM 2013, 'Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis', Annals of Surgical Oncology, vol. 20, no. 12, pp. 3779-3786. https://doi.org/10.1245/s10434-013-3127-y
Hyder, Omar ; Marsh, J. Wallis ; Salem, Riad ; Petre, Elena N. ; Kalva, Sanjeeva ; Liapi, Eleni ; Cosgrove, David ; Neal, Donielle ; Kamel, Ihab ; Zhu, Andrew X. ; Sofocleous, Constantinos T. ; Geschwind, Jean Francois H ; Pawlik, Timothy M. / Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma : A multi-institutional analysis. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 12. pp. 3779-3786.
@article{c395e3ee22634dc58b017d85c98a9667,
title = "Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis",
abstract = "Background: Many patients with intrahepatic cholangiocarcinoma (ICC) present with advanced and inoperable disease. Data on the safety and efficacy of intra-arterial therapy (IAT) for ICC are limited. Methods: Between 1992 and 2012, a total of 198 patients with advanced ICC treated with IAT were retrospectively identified from the databases of five major hepatobiliary institutions. Data on clinicopathological factors, morbidity, response rates, and overall survival were collected and analyzed. Results: Median patient age was 61 years. Median tumor size was 8.1 cm, and 47.5 {\%} patients had a solitary lesion. IAT consisted of conventional transarterial chemoembolization (cTACE) (64.7 {\%}), drug-eluting beads (DEB) (5.6 {\%}), bland embolization (TAE) (6.6 {\%}), or yttrium-90 radioembolization (23.2 {\%}). Median number of IAT sessions was 2 (range 1-8). The median time between IAT sessions was 48 days. The periprocedural morbidity was 29.8 {\%}; most complications were minor (n = 43); however, 16 patients had a grade 3-4 complication. Assessment of tumor response revealed complete or partial response in 25.5 {\%} patients, while 61.5 {\%} had stable disease; 13.0 {\%} had progressive disease. Median overall survival was 13.2 months and did not differ on the basis of the type of IAT (cTACE, 13.4 months vs. DEB 10.5 months vs. TAE, 14.3 months vs. yttrium-90, 11.3 months; P = 0.46). IAT response on modified response evaluation criteria in solid tumors (mRECIST; hazard ratio for complete-partial response 0.49, 95 {\%} confidence interval 0.30-0.81; P < 0.001) was independently associated with better survival. Conclusions: IAT for ICC was safe and led to stable disease or partial to complete response in up to three-quarters of patients. Among patients with an IAT response, overall survival was prolonged. The role of IAT therapy for ICC warrants further prospective evaluation in clinical trials.",
author = "Omar Hyder and Marsh, {J. Wallis} and Riad Salem and Petre, {Elena N.} and Sanjeeva Kalva and Eleni Liapi and David Cosgrove and Donielle Neal and Ihab Kamel and Zhu, {Andrew X.} and Sofocleous, {Constantinos T.} and Geschwind, {Jean Francois H} and Pawlik, {Timothy M.}",
year = "2013",
month = "11",
doi = "10.1245/s10434-013-3127-y",
language = "English (US)",
volume = "20",
pages = "3779--3786",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma

T2 - A multi-institutional analysis

AU - Hyder, Omar

AU - Marsh, J. Wallis

AU - Salem, Riad

AU - Petre, Elena N.

AU - Kalva, Sanjeeva

AU - Liapi, Eleni

AU - Cosgrove, David

AU - Neal, Donielle

AU - Kamel, Ihab

AU - Zhu, Andrew X.

AU - Sofocleous, Constantinos T.

AU - Geschwind, Jean Francois H

AU - Pawlik, Timothy M.

PY - 2013/11

Y1 - 2013/11

N2 - Background: Many patients with intrahepatic cholangiocarcinoma (ICC) present with advanced and inoperable disease. Data on the safety and efficacy of intra-arterial therapy (IAT) for ICC are limited. Methods: Between 1992 and 2012, a total of 198 patients with advanced ICC treated with IAT were retrospectively identified from the databases of five major hepatobiliary institutions. Data on clinicopathological factors, morbidity, response rates, and overall survival were collected and analyzed. Results: Median patient age was 61 years. Median tumor size was 8.1 cm, and 47.5 % patients had a solitary lesion. IAT consisted of conventional transarterial chemoembolization (cTACE) (64.7 %), drug-eluting beads (DEB) (5.6 %), bland embolization (TAE) (6.6 %), or yttrium-90 radioembolization (23.2 %). Median number of IAT sessions was 2 (range 1-8). The median time between IAT sessions was 48 days. The periprocedural morbidity was 29.8 %; most complications were minor (n = 43); however, 16 patients had a grade 3-4 complication. Assessment of tumor response revealed complete or partial response in 25.5 % patients, while 61.5 % had stable disease; 13.0 % had progressive disease. Median overall survival was 13.2 months and did not differ on the basis of the type of IAT (cTACE, 13.4 months vs. DEB 10.5 months vs. TAE, 14.3 months vs. yttrium-90, 11.3 months; P = 0.46). IAT response on modified response evaluation criteria in solid tumors (mRECIST; hazard ratio for complete-partial response 0.49, 95 % confidence interval 0.30-0.81; P < 0.001) was independently associated with better survival. Conclusions: IAT for ICC was safe and led to stable disease or partial to complete response in up to three-quarters of patients. Among patients with an IAT response, overall survival was prolonged. The role of IAT therapy for ICC warrants further prospective evaluation in clinical trials.

AB - Background: Many patients with intrahepatic cholangiocarcinoma (ICC) present with advanced and inoperable disease. Data on the safety and efficacy of intra-arterial therapy (IAT) for ICC are limited. Methods: Between 1992 and 2012, a total of 198 patients with advanced ICC treated with IAT were retrospectively identified from the databases of five major hepatobiliary institutions. Data on clinicopathological factors, morbidity, response rates, and overall survival were collected and analyzed. Results: Median patient age was 61 years. Median tumor size was 8.1 cm, and 47.5 % patients had a solitary lesion. IAT consisted of conventional transarterial chemoembolization (cTACE) (64.7 %), drug-eluting beads (DEB) (5.6 %), bland embolization (TAE) (6.6 %), or yttrium-90 radioembolization (23.2 %). Median number of IAT sessions was 2 (range 1-8). The median time between IAT sessions was 48 days. The periprocedural morbidity was 29.8 %; most complications were minor (n = 43); however, 16 patients had a grade 3-4 complication. Assessment of tumor response revealed complete or partial response in 25.5 % patients, while 61.5 % had stable disease; 13.0 % had progressive disease. Median overall survival was 13.2 months and did not differ on the basis of the type of IAT (cTACE, 13.4 months vs. DEB 10.5 months vs. TAE, 14.3 months vs. yttrium-90, 11.3 months; P = 0.46). IAT response on modified response evaluation criteria in solid tumors (mRECIST; hazard ratio for complete-partial response 0.49, 95 % confidence interval 0.30-0.81; P < 0.001) was independently associated with better survival. Conclusions: IAT for ICC was safe and led to stable disease or partial to complete response in up to three-quarters of patients. Among patients with an IAT response, overall survival was prolonged. The role of IAT therapy for ICC warrants further prospective evaluation in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84886099586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886099586&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3127-y

DO - 10.1245/s10434-013-3127-y

M3 - Article

C2 - 23846786

AN - SCOPUS:84886099586

VL - 20

SP - 3779

EP - 3786

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -